Tumor necrosis factor α-gene therapy for an established murine melanoma using RGD (Arg-Gly-Asp) fiber-mutant adenovirus vectors

Although adenovirus vectors (Ad) provide high-level transduction efficacy to many cell types, extremely high doses of Ad are required for sufficient gene transduction into several tumors, including melanoma. Here, we demonstrated that the expression of coxsackie-adenovirus receptor, a primitive Ad-r...

Full description

Saved in:
Bibliographic Details
Published inJapanese journal of cancer research (Gann) Vol. 93; no. 4; pp. 436 - 444
Main Authors OKADA, Yuka, OKADA, Naoki, NAKAGAWA, Shinsaku, MIZUGUCHI, Hiroyuki, TAKAHASHI, Koichi, MIZUNO, Nobuyasu, FUJITA, Takuya, YAMAMOTO, Akira, HAYAKAWA, Takao, MAYMI, Tadanori
Format Journal Article
LanguageEnglish
Published Tokyo Japanese Cancer Association 01.04.2002
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Although adenovirus vectors (Ad) provide high-level transduction efficacy to many cell types, extremely high doses of Ad are required for sufficient gene transduction into several tumors, including melanoma. Here, we demonstrated that the expression of coxsackie-adenovirus receptor, a primitive Ad-receptor, was very low in murine and human melanoma cells. We also found that fiber-mutant Ad containing the Arg-Gly-Asp (RGD) sequence in the fiber knob remarkably augmented gene transduction efficacy in melanoma cells by targeting alpha(v)-integrins. In addition, intratumoral injection of RGD fiber-mutant Ad containing the tumor necrosis factor alpha gene (Ad-RGD-TNFalpha) revealed dramatic anti-tumor efficacy through hemolytic necrosis in an established murine B16 BL6 melanoma model. Ad-RGD-TNFalpha required one-tenth the dosage of Ad-TNFalpha to induce an equal therapeutic effect. These results suggest that alpha(v)-integrin-targeted Ad will be a very powerful tool for the advancement of melanoma gene therapy.
AbstractList Although adenovirus vectors (Ad) provide high-level transduction efficacy to many cell types, extremely high doses of Ad are required for sufficient gene transduction into several tumors, including melanoma. Here, we demonstrated that the expression of coxsackie-adenovirus receptor, a primitive Ad-receptor, was very low in murine and human melanoma cells. We also found that fiber-mutant Ad containing the Arg-Gly-Asp (RGD) sequence in the fiber knob remarkably augmented gene transduction efficacy in melanoma cells by targeting alpha(v)-integrins. In addition, intratumoral injection of RGD fiber-mutant Ad containing the tumor necrosis factor alpha gene (Ad-RGD-TNFalpha) revealed dramatic anti-tumor efficacy through hemolytic necrosis in an established murine B16 BL6 melanoma model. Ad-RGD-TNFalpha required one-tenth the dosage of Ad-TNFalpha to induce an equal therapeutic effect. These results suggest that alpha(v)-integrin-targeted Ad will be a very powerful tool for the advancement of melanoma gene therapy.
Author TAKAHASHI, Koichi
NAKAGAWA, Shinsaku
MIZUNO, Nobuyasu
FUJITA, Takuya
YAMAMOTO, Akira
OKADA, Yuka
MIZUGUCHI, Hiroyuki
HAYAKAWA, Takao
MAYMI, Tadanori
OKADA, Naoki
Author_xml – sequence: 1
  givenname: Yuka
  surname: OKADA
  fullname: OKADA, Yuka
  organization: Department of Pharmaceutics, School of Pharmaceutical Sciences, Mukogawa Women's University, II-68, Kyuban-cho, Koshien, Nishinomiya, Hyogo 663-8179, Japan
– sequence: 2
  givenname: Naoki
  surname: OKADA
  fullname: OKADA, Naoki
  organization: Department of Biopharmaceutics, Kyoto Pharmaceutical University, Misasagi, Yamashina-ku, Kyoto 607-8414, Japan
– sequence: 3
  givenname: Shinsaku
  surname: NAKAGAWA
  fullname: NAKAGAWA, Shinsaku
  organization: Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan
– sequence: 4
  givenname: Hiroyuki
  surname: MIZUGUCHI
  fullname: MIZUGUCHI, Hiroyuki
  organization: Division of Biological Chemtistry and Biologicals, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan
– sequence: 5
  givenname: Koichi
  surname: TAKAHASHI
  fullname: TAKAHASHI, Koichi
  organization: Department of Pharmaceutics, School of Pharmaceutical Sciences, Mukogawa Women's University, II-68, Kyuban-cho, Koshien, Nishinomiya, Hyogo 663-8179, Japan
– sequence: 6
  givenname: Nobuyasu
  surname: MIZUNO
  fullname: MIZUNO, Nobuyasu
  organization: Department of Pharmaceutics, School of Pharmaceutical Sciences, Mukogawa Women's University, II-68, Kyuban-cho, Koshien, Nishinomiya, Hyogo 663-8179, Japan
– sequence: 7
  givenname: Takuya
  surname: FUJITA
  fullname: FUJITA, Takuya
  organization: Department of Biopharmaceutics, Kyoto Pharmaceutical University, Misasagi, Yamashina-ku, Kyoto 607-8414, Japan
– sequence: 8
  givenname: Akira
  surname: YAMAMOTO
  fullname: YAMAMOTO, Akira
  organization: Department of Biopharmaceutics, Kyoto Pharmaceutical University, Misasagi, Yamashina-ku, Kyoto 607-8414, Japan
– sequence: 9
  givenname: Takao
  surname: HAYAKAWA
  fullname: HAYAKAWA, Takao
  organization: Division of Biological Chemtistry and Biologicals, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan
– sequence: 10
  givenname: Tadanori
  surname: MAYMI
  fullname: MAYMI, Tadanori
  organization: Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13877735$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/11985794$$D View this record in MEDLINE/PubMed
BookMark eNpF0M1q3DAQAGBREppN2lcoopDQHOSO_izruKTtJhAIlPS8yPZoo8WWN5Idsre8Ul6kz1SXbokug4aP-TslR3GISMhnDgWf39dtwaWyzACUhQAQxVgDF0YXz-_IglemZKo08ogswHJgGjSckNOctwDcQCnekxPObaWNVQvycj_1Q6IRmzTkkKl3zTj_f7-yDUak4wMmt9tTP-dcpJhHV3chP2BL-ymFWfTYuTj0jk45xA39ufpGvyzThq26PVvm3SX1ocbE-ml0caSuxTg8hTRl-oR_O-UP5Ni7LuPHQzwjv358v7-6Zrd3q5ur5S3bCitGVkmvhUYu21o71ChaLmtXN8YLLEUlQUnkTtZCWFACrPIWufYaUDrFq0aekYt_dXdpeJzmRdZ9yA128_Q4THlteKkqadUMPx3gVPfYrncp9C7t1_9vNoPzA3C5cZ1PLjYhvzlZGWOkln8ArpuBRA
CODEN GANNA2
ContentType Journal Article
Copyright 2002 INIST-CNRS
Copyright_xml – notice: 2002 INIST-CNRS
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1111/j.1349-7006.2002.tb01275.x
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1876-4673
EndPage 444
ExternalDocumentID 11985794
13877735
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID --K
.55
.GA
.GJ
10A
1B1
1OC
2WC
3O-
51W
51X
52N
52O
52P
52R
52S
52T
52W
52X
53G
5HH
5LA
5RE
66C
7PT
930
A01
A03
AAHHS
AAUGY
ACCFJ
ACGFS
ACXQS
ADBBV
ADZOD
AEEZP
AEQDE
AFFNX
AFZJQ
AI.
AIWBW
AJBDE
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BY8
DIK
F5P
HOLLA
HYE
HZI
IHE
IQODW
JSF
JSH
KQ8
LP6
LP7
M41
NQ-
OK1
P4B
P4D
QB0
RJT
ROL
RPM
RPZ
RZJ
SUPJJ
UDS
VH1
WQJ
WXI
X7M
XG1
ZGI
ZXP
ABJNI
ALUQN
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-j292t-83f525e13db5ae5e2d13babc7f2e6283043e1a3b229042094f9e15f50e3a418c3
ISSN 0910-5050
IngestDate Fri Aug 16 04:38:45 EDT 2024
Sat Sep 28 08:34:57 EDT 2024
Sun Oct 22 16:06:08 EDT 2023
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Issue 4
Keywords Adenoviridae
Cytokine
Rodentia
Melanoma
Tripeptide
Malignant tumor
Virus
Vertebrata
Mammalia
Treatment
Gene
Mouse
Animal
Established cell line
Genetic engineering
Transduction
Mutation
Gene therapy
Vector
Tumor necrosis factor α
Biological receptor
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-j292t-83f525e13db5ae5e2d13babc7f2e6283043e1a3b229042094f9e15f50e3a418c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 11985794
PQID 71648394
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_71648394
pubmed_primary_11985794
pascalfrancis_primary_13877735
PublicationCentury 2000
PublicationDate 2002-04-01
PublicationDateYYYYMMDD 2002-04-01
PublicationDate_xml – month: 04
  year: 2002
  text: 2002-04-01
  day: 01
PublicationDecade 2000
PublicationPlace Tokyo
PublicationPlace_xml – name: Tokyo
– name: Japan
PublicationTitle Japanese journal of cancer research (Gann)
PublicationTitleAlternate Jpn J Cancer Res
PublicationYear 2002
Publisher Japanese Cancer Association
Publisher_xml – name: Japanese Cancer Association
SSID ssj0017062
Score 1.3759363
Snippet Although adenovirus vectors (Ad) provide high-level transduction efficacy to many cell types, extremely high doses of Ad are required for sufficient gene...
SourceID proquest
pubmed
pascalfrancis
SourceType Aggregation Database
Index Database
StartPage 436
SubjectTerms Adenoviridae - genetics
Animals
Antibodies, Monoclonal - metabolism
Biological and medical sciences
Cell Line, Tumor
Cricetinae
Enterovirus - genetics
Flow Cytometry
Gene Transfer Techniques
Genetic Therapy - methods
Genetic Vectors
Green Fluorescent Proteins - metabolism
HeLa Cells
Humans
Integrin alphaV - metabolism
Lac Operon
Medical sciences
Melanoma - metabolism
Melanoma - therapy
Melanoma, Experimental - therapy
Mice
Mice, Inbred C57BL
Mutation
Necrosis
Oligopeptides - chemistry
Oligopeptides - pharmacology
Other treatments
Polymerase Chain Reaction
Protein Binding
Reverse Transcriptase Polymerase Chain Reaction
Time Factors
Treatment. General aspects
Tumor Necrosis Factor-alpha - genetics
Tumors
Title Tumor necrosis factor α-gene therapy for an established murine melanoma using RGD (Arg-Gly-Asp) fiber-mutant adenovirus vectors
URI https://www.ncbi.nlm.nih.gov/pubmed/11985794
https://search.proquest.com/docview/71648394
Volume 93
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwFLbKkBAXxG_Kj-EDB1Bk1MRO0x4rBhug7QCbNE6V4zhdyJJUSTPUXfmL-A95z3bbDKgEXKLKltMo74vf8_Pz9xHywlB8jxIAr5JjJkQYsDhSKcNNHCSk85XRTzk8Gh6ciA-n4Wmv96NTtdQu4tfq8o_nSv7HqtAGdsVTsv9g2fVNoQF-g33hChaG69_ZuC2q2is1urqscdo5njk-y2CQ9uzpqqUrlfTAA0hbBZ94BabZtVfoc1lWhfRakzT4tL-HMeeknrH98yWbNHNMG6RYVsKKFhWHPQkzVXWR1W3jXZiUf3MlwAXni6KWXUoKhciqPccrdGYyE0abeZPizWViotgvbS5_azySVZ6ts9YylzP5zXR8PsvKRubtGjXZZTtDdRfjULO6WrZu4CqvEXTKYVyCEjwExGeD7lxt1RQdJkVn4hWWRmW7Q-BizCLcesL_wnw4MtvbUtEOUuaFgYoP-A0jq778Cx33qusauR7A3IZVhHvvP643rqKB0bBdP7zjuXXFY1seAplr3W2xNlc28HmmVldl-8LHBEDHt8ktt3KhEwvDO6Sny7vkxqGrzbhHvhs00hUaqUUj3aCROjTSFJtL2kEjtWikKzRSg0YKaKQvO1h8RbtIpBskUofE--Tk3dvjNwfMSXywr8E4WLART8Mg1D5P4lDqUAeJz2MZqygN9BC56QTXvuQxqhKIYDAW6Vj7YRoONJfCHyn-gOyUVakfEZoMIyGVEJHmQxHzSCoVpBqGqsFI-sLvk90rb3Y6t3QuU58jJyYP--T56lVPYY7FjTP4YKq2mWJOARYSok8eWgtsxjqzPd7a84Tc3KD7KdlZ1K1-BnHsIt41yPkJfjWcTg
link.rule.ids 315,783,787,27938,27939
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tumor+necrosis+factor+alpha-gene+therapy+for+an+established+murine+melanoma+using+RGD+%28Arg-Gly-Asp%29+fiber-mutant+adenovirus+vectors&rft.jtitle=Japanese+journal+of+cancer+research+%28Gann%29&rft.au=Okada%2C+Yuka&rft.au=Okada%2C+Naoki&rft.au=Nakagawa%2C+Shinsaku&rft.au=Mizuguchi%2C+Hiroyuki&rft.date=2002-04-01&rft.issn=0910-5050&rft.volume=93&rft.issue=4&rft.spage=436&rft_id=info:doi/10.1111%2Fj.1349-7006.2002.tb01275.x&rft_id=info%3Apmid%2F11985794&rft.externalDocID=11985794
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0910-5050&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0910-5050&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0910-5050&client=summon